Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Operating Leases: 2022-2025

Historic Operating Leases for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $305,755.

  • InMed Pharmaceuticals' Operating Leases fell 79.63% to $215,478 in Q3 2025 from the same period last year, while for Sep 2025 it was $215,478, marking a year-over-year decrease of 79.63%. This contributed to the annual value of $305,755 for FY2025, which is 52.59% down from last year.
  • According to the latest figures from FY2025, InMed Pharmaceuticals' Operating Leases is $305,755, which was down 52.59% from $644,865 recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Operating Leases registered a high of $644,865 during FY2024, and its lowest value of $15,994 during FY2023.
  • Its 3-year average for Operating Leases is $322,205, with a median of $305,755 in 2025.
  • Per our database at Business Quant, InMed Pharmaceuticals' Operating Leases tumbled by 95.89% in 2023 and then surged by 3,931.92% in 2024.
  • InMed Pharmaceuticals' Operating Leases (Yearly) stood at $389,498 in 2022, then crashed by 95.89% to $15,994 in 2023, then soared by 3,931.92% to $644,865 in 2024, then tumbled by 52.59% to $305,755 in 2025.